TrialLung cancer (Amsterdam, Netherlands)2022

Ramucirumab plus atezolizumab in patients with stage IV non-small cell lung cancer previously treated with immune checkpoint inhibitors.

Brett H Herzog et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.